Voyager Therapeutics, Inc. Common Stock (VYGR) — Analysis Summary
Voyager Therapeutics, Inc. Common Stock (VYGR) has a market cap of $195.76M with year-over-year revenue growth of -49.5%. Net margin stands at -296.5%. The stock trades at a P/E ratio of -1.7.
Key Takeaways
- Revenue changed -49.5% year-over-year
- Net margin of -296.5%
- P/E ratio of -1.7
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, VYGR posted revenue growth of -49.5% and trades at a P/E of -1.7.
Voyager Therapeutics, Inc. Common Stock (VYGR)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -349.2% — severe operating losses
Net margin at -319.6% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
141
Headquarters
LEXINGTON, MA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.